Globus Medical Reports Third Quarter 2021 Results

Rhea-AI Summary

Globus Medical, Inc. (NYSE: GMED) reported its financial results for Q3 2021, highlighting worldwide net sales of $229.7 million, a 6.3% increase year-over-year. GAAP net income was $47.2 million, or 20.6% of sales, reflecting a 6.8% rise. Diluted EPS stood at $0.45 GAAP and $0.50 non-GAAP. Notably, U.S. sales rose 8.8%, while international sales declined 7.2%. The company confirmed full-year guidance of $950 million in net sales and $2.00 in non-GAAP EPS. Cash reserves total $985 million, maintaining a debt-free status.

Positive

• Net sales increased by 6.3% year-over-year to $229.7 million.
• GAAP net income rose 6.8% to $47.2 million.
• U.S. net sales grew by 8.8%, indicating strong domestic market performance.
• The company maintained a debt-free balance sheet with $985 million in cash and equivalents.
• Confirmed guidance of $950 million in net sales and $2.00 non-GAAP EPS for 2021.

Negative

• International net sales decreased by 7.2%, indicating challenges in foreign markets.

AUDUBON, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2021.

• Worldwide net sales were $229.7 million, an increase of 6.3% as compared to the third quarter of 2020
  
  
• GAAP net income for the quarter was $47.2 million, or 20.6% of net sales, which is an increase of 6.8% as compared to the third quarter of 2020
  
  
• GAAP diluted earnings per share (“EPS”) was $0.45 and non-GAAP diluted EPS was $0.50
  
  
• Non-GAAP adjusted EBITDA was $78.3 million, or 34.1% of net sales
  

“Revenue in the third quarter was $230 million, an increase of more than 6% over the third quarter of 2020, as we continue to capture market share and perform well above our peers,” said Dave Demski, President and CEO. “Our strong revenue performance in the quarter, in spite of continuing COVID-related headwinds, combined with growing momentum in Enabling Technology; our best recruiting quarter in over a year; and FDA 510(k) clearances for Excelsius3D™ and ExcelsiusHUB™ provide the platform for growth acceleration into 2022 and beyond.”

Worldwide net sales for the third quarter of 2021 was $229.7 million, an as-reported increase of 6.3% over the third quarter of 2020. U.S. net sales for the third quarter of 2021, including robotics, increased by 8.8% compared to the third quarter of 2020. International net sales for the third quarter of 2021 decreased by 7.2% over the third quarter of 2020.

GAAP net income for the third quarter of 2021 was $47.2 million, an increase of 6.8% over the same period last year. GAAP diluted EPS for the third quarter of 2021 was $0.45, compared to $0.44 for the third quarter 2020. Non-GAAP diluted EPS for the third quarter of 2021 was $0.50, compared to $0.49 in the third quarter of 2020, an increase of 3.3%.

The Company generated net cash from operating activities of $77.3 million and non-GAAP free cash flow of $59.5 million during the third quarter of 2021. Cash, cash equivalents and marketable securities were $985.0 million as of September 30, 2021. The Company remains debt free.

2021 Annual Guidance

The Company today reaffirmed its full year 2021 guidance of $950 million in net sales and non-GAAP diluted earnings per share of $2.00.

Conference Call Information

Globus Medical will hold a teleconference to discuss its third quarter 2021 results with the investment community at 4:30 p.m. Eastern Time today. Globus invites all interested parties to join the call by dialing:

1-877-313-2501 United States Participants
1-929-517-0907 International Participants

There is no pass code for the teleconference.

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at www.globusmedical.com/investors.

The call will be archived until Thursday, November 11, 2021. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 107-3064.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.

Non-GAAP Financial Measures

To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, acquisition related costs/licensing, and acquisition of in-process research and development, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Acquisition related costs/licensing represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees, as well as one-time licensing fees. Acquisition of in-process research and development represents the expensing of acquired assets with no alternative future use and related fees.

In addition, for the period ended September 30, 2021 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP Diluted Earnings Per Share, which represent net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, acquisition related costs/licensing, acquisition of in-process research and development, and the tax effects of all of the foregoing adjustments. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of litigation, amortization of intangibles, acquisition related costs/licensing, acquisition of in-process research and development, and the tax effects of all of the foregoing adjustments, which we believe are not reflective of underlying business trends. Additionally, for the period ended September 30, 2021 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment.  We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions.  Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period.  We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency net sales growth are not calculated in conformity with U.S. GAAP.  Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP.  These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results.  Our definitions of non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency net sales growth may differ from that of other companies and therefore may not be comparable.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

GLOBUS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited)
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
(In thousands, except per share amounts)		2021				2020				2021				2020
Net sales		$	229,721			$	216,098			$	708,081			$	555,597
Cost of goods sold			58,554				57,097				177,427				156,604
Gross profit			171,167				159,001				530,654				398,993
Operating expenses:
Research and development			15,853				14,421				46,324				69,278
Selling, general and administrative			96,444				89,152				301,589				262,710
Provision for litigation			605				—				511				197
Amortization of intangibles			4,573				4,152				13,970				12,043
Acquisition related costs			363				1,263				14,507				1,867
Total operating expenses			117,838				108,988				376,901				346,095
Operating income/(loss)			53,329				50,013				153,753				52,898
Other income/(expense), net:
Interest income/(expense), net			2,105				3,085				7,358				10,999
Foreign currency transaction gain/(loss)			(898	)			(170	)			(969	)			(806	)
Other income/(expense)			(84	)			202				437				595
Total other income/(expense), net			1,123				3,117				6,826				10,788
Income/(loss) before income taxes			54,452				53,130				160,579				63,686
Income tax provision			7,241				8,914				26,494				14,358
Net income/(loss)		$	47,211			$	44,216			$	134,085			$	49,328
Other comprehensive income/(loss):
Unrealized gain/(loss) on marketable securities, net of tax			(991	)			(770	)			(3,431	)			2,285
Foreign currency translation gain/(loss)			(491	)			1,679				(3,578	)			2,820
Total other comprehensive income/(loss)			(1,482	)			909				(7,009	)			5,105
Comprehensive income/(loss)		$	45,729			$	45,125			$	127,076			$	54,433
Earnings per share:
Basic		$	0.47			$	0.45			$	1.33			$	0.50
Diluted		$	0.45			$	0.44			$	1.30			$	0.49
Weighted average shares outstanding:
Basic			101,104				98,217				100,477				98,453
Diluted			104,418				100,485				103,430				100,823

GLOBUS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
		September 30,				December 31,
(In thousands, except share and per share values)		2021				2020
ASSETS
Current assets:
Cash, cash equivalents, and restricted cash		$	361,876			$	239,397
Short-term marketable securities			191,319				187,344
Accounts receivable, net of allowances of $4,930 and $4,408, respectively			159,576				141,676
Inventories			234,368				229,153
Prepaid expenses and other current assets			16,207				17,771
Income taxes receivable			17,168				6,424
Total current assets			980,514				821,765
Property and equipment, net of accumulated depreciation of $301,163 and $276,451, respectively			215,665				216,879
Long-term marketable securities			431,814				358,522
Intangible assets, net			73,095				86,949
Goodwill			166,578				156,716
Other assets			33,574				32,039
Deferred income taxes			9,338				6,615
Total assets		$	1,910,578			$	1,679,485
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable		$	20,678			$	18,205
Accrued expenses			81,480				78,334
Income taxes payable			1,971				1,101
Business acquisition liabilities			8,729				5,777
Deferred revenue			9,667				8,125
Payable to broker			—				9,250
Total current liabilities			122,525				120,792
Business acquisition liabilities, net of current portion			49,113				31,493
Deferred income taxes			4,792				6,202
Other liabilities			15,879				14,701
Total liabilities			192,309				173,188
Equity:
Class A common stock; $0.001 par value. Authorized 500,000,000 shares; issued and outstanding 79,029,625 and 77,284,007 shares at September 30, 2021 and December 31, 2020, respectively			79				77
Class B common stock; $0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22,430,097 shares at September 30, 2021 and December 31, 2020			22				22
Additional paid-in capital			542,055				457,161
Accumulated other comprehensive income (loss)			(3,054	)			3,955
Retained earnings			1,179,167				1,045,082
Total equity			1,718,269				1,506,297
Total liabilities and equity		$	1,910,578			$	1,679,485

GLOBUS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
		Nine Months Ended
		September 30,
(In thousands)		2021				2020
Cash flows from operating activities:
Net income		$	134,085			$	49,328
Adjustments to reconcile net income to net cash provided by operating activities:
Acquired in-process research and development			—				24,418
Depreciation and amortization			53,038				45,970
Amortization of premium (discount) on marketable securities			1,763				215
Write-down of excess and obsolete inventories			5,570				12,411
Stock-based compensation expense			22,781				21,138
Allowance for doubtful accounts			883				2,741
Change in fair value of business acquisition liabilities			14,336				1,027
Change in deferred income taxes			(3,131	)			(4,458	)
(Gain)/loss on disposal of assets, net			383				714
Payment of business acquisition related liabilities			—				(700	)
(Increase)/decrease in:
Accounts receivable			(19,928	)			8,412
Inventories			(9,161	)			(47,271	)
Prepaid expenses and other assets			(794	)			(4,381	)
Increase/(decrease) in:
Accounts payable			2,521				5,401
Accrued expenses and other liabilities			7,500				3,749
Income taxes payable/receivable			(9,825	)			(105	)
Net cash provided by/(used in) operating activities			200,021				118,609
Cash flows from investing activities:
Purchases of marketable securities			(347,057	)			(57,418	)
Maturities of marketable securities			171,886				100,830
Sales of marketable securities			82,882				39,944
Purchases of property and equipment			(39,853	)			(49,595	)
Acquisition of businesses, net of cash acquired, and purchases of intangible and other assets			—				(31,991	)
Net cash provided by/(used in) investing activities			(132,142	)			1,770
Cash flows from financing activities:
Payment of business acquisition related liabilities			(4,763	)			(5,327	)
Proceeds from exercise of stock options			59,933				44,121
Repurchase of common stock			—				(104,669	)
Net cash provided by/(used in) financing activities			55,170				(65,875	)
Effect of foreign exchange rates on cash			(570	)			379
Net increase in cash, cash equivalents, and restricted cash			122,479				54,883
Cash, cash equivalents, and restricted cash at beginning of period			239,397				195,724
Cash, cash equivalents, and restricted cash at end of period		$	361,876			$	250,607
Supplemental disclosures of cash flow information:
Income taxes paid		$	39,450			$	19,328
Purchases of property and equipment included in accounts payable and accrued expenses		$	3,491			$	3,931

Supplemental Financial Information
Net Sales by Product Category:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
(In thousands)		2021			2020			2021			2020
Musculoskeletal Solutions		$	209,478		$	207,063		$	652,157		$	533,085
Enabling Technologies			20,243			9,035			55,924			22,512
Total net sales		$	229,721		$	216,098		$	708,081		$	555,597

Liquidity and Capital Resources:
		September 30,			December 31,
(In thousands)		2021			2020
Cash, cash equivalents, and restricted cash		$	361,876		$	239,397
Short-term marketable securities			191,319			187,344
Long-term marketable securities			431,814			358,522
Total cash, cash equivalents, restricted cash and marketable securities		$	985,009		$	785,263

The following tables reconcile GAAP to Non-GAAP financial measures.

Non-GAAP Adjusted EBITDA Reconciliation Table:
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
(In thousands, except percentages)		2021				2020				2021				2020
Net income/(loss)		$	47,211			$	44,216			$	134,085			$	49,328
Interest income/(expense), net			(2,105	)			(3,085	)			(7,358	)			(10,999	)
Provision for income taxes			7,241				8,914				26,494				14,358
Depreciation and amortization			16,751				16,301				53,038				45,970
EBITDA			69,098				66,346				206,259				98,657
Stock-based compensation expense			7,451				7,020				22,781				21,138
Provision for litigation			605				—				511				197
Acquisition related costs/licensing			1,181				1,753				16,688				3,179
Acquisition of in-process research and development			—				—				—				24,418
Adjusted EBITDA		$	78,335			$	75,119			$	246,239			$	147,589
Net income as a percentage of net sales			20.6	%			20.5	%			18.9	%			8.9	%
Adjusted EBITDA as a percentage of net sales			34.1	%			34.8	%			34.8	%			26.6	%

Non-GAAP Net Income Reconciliation Table:
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
(In thousands)		2021				2020				2021				2020
Net income/(loss)		$	47,211			$	44,216			$	134,085			$	49,328
Provision for litigation			605				—				511				197
Amortization of intangibles			4,573				4,152				13,970				12,043
Acquisition related costs/licensing			1,181				1,753				16,688				3,179
Acquisition of in-process research and development			—				—				—				24,418
Tax effect of adjusting items			(846	)			(992	)			(4,906	)			(3,418	)
Non-GAAP net income		$	52,724			$	49,129			$	160,348			$	85,747

Non-GAAP Diluted Earnings Per Share Reconciliation Table:
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
(Per share amounts)		2021				2020				2021				2020
Diluted earnings per share, as reported		$	0.45			$	0.44			$	1.30			$	0.49
Provision for litigation			—				—				—				—
Amortization of intangibles			0.05				0.04				0.14				0.12
Acquisition related costs/licensing			0.01				0.02				0.16				0.03
Acquisition of in-process research and development			—				—				—				0.24
Tax effect of adjusting items			(0.01	)			(0.01	)			(0.05	)			(0.03	)
Non-GAAP diluted earnings per share		$	0.50			$	0.49			$	1.55			$	0.85
* Amounts might not add due to rounding

Non-GAAP Free Cash Flow Reconciliation Table:
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
(In thousands)		2021				2020				2021				2020
Net cash provided by/(used in) operating activities		$	77,262			$	53,248			$	200,021			$	118,609
Purchases of property and equipment			(17,795	)			(17,325	)			(39,853	)			(49,595	)
Free cash flow		$	59,467			$	35,923			$	160,168			$	69,014

Net Sales on a Constant Currency Basis Comparative Table:
		Three Months Ended						Reported			Currency Impact on			Constant Currency
		September 30,						Net Sales			Current			Net Sales
(In thousands, except percentages)		2021			2020			Growth			Period Net Sales			Growth
United States		$	198,172		$	182,104		8.8	%		$	—		8.8	%
International			31,549			33,994		-7.2	%			144		-7.6	%
Total net sales		$	229,721		$	216,098		6.3	%		$	144		6.2	%

		Nine Months Ended						Reported			Currency Impact on			Constant Currency
		September 30,						Net Sales			Current			Net Sales
(In thousands, except percentages)		2021			2020			Growth			Period Net Sales			Growth
United States		$	606,608		$	465,705		30.3	%		$	—		30.3	%
International			101,473			89,892		12.9	%			2,259		10.4	%
Total net sales		$	708,081		$	555,597		27.4	%		$	2,259		27.0	%

Contact:
Brian Kearns
Senior Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com 
www.globusmedical.com 

FAQ

What were Globus Medical's Q3 2021 financial results?

Globus Medical reported Q3 2021 net sales of $229.7 million, a 6.3% increase year-over-year, with GAAP net income of $47.2 million.

How much was Globus Medical's diluted EPS in Q3 2021?

The GAAP diluted EPS for Q3 2021 was $0.45, with a non-GAAP diluted EPS of $0.50.

What is the 2021 guidance for Globus Medical?

Globus Medical reaffirmed its 2021 guidance at $950 million in net sales and $2.00 in non-GAAP diluted EPS.

What are the cash reserves of Globus Medical as of September 30, 2021?

As of September 30, 2021, Globus Medical had cash, cash equivalents, and marketable securities totaling $985 million.

Did Globus Medical experience growth in U.S. sales?

Yes, U.S. net sales increased by 8.8% in Q3 2021 compared to the same period last year.